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Concurrent chemotherapy and thoracic radiotherapy (TRT) is recommended for limited 
disease small-cell lung cancer (LD SCLC). Twice daily TRT is well documented, but 
not universally implemented – probably mainly due to inconvenience and concerns 
about toxicity. A schedule of 3-week hypofractionated TRT is a commonly used 
alternative. This is the first randomized trial comparing twice-daily and 
hypofractionated TRT in LD SCLC. 
 
Materials and Methods 
Patients received four courses of cisplatin/etoposide (PE) and were randomized to TRT 
of 42 Gy in 15 fractions (once daily - OD) or 45 Gy in 30 fractions (twice-daily - BID) 
between the second and third PE-course. Good responders received prophylactic cranial 
irradiation of 30 Gy in 15 fractions. 
 
Results 
157 patients were enrolled between May 2005 and January 2011 (OD: n=84, BID: 
n=73). Median age was 63 years, 52% were men, 84% had performance status 0-1, 72% 
had stage III disease and 11% non-malignant pleural effusion. The treatment arms were 
well balanced. The response rates were similar (OD: 92%, BID: 88%; p=.41), but more 
BID-patients achieved a complete response (OD: 13%, BID: 33%; p=.003). There was 
no difference in 1-year PFS (OD: 45%, BID: 49%; p=.61) or median PFS (OD: 10.2 
months, BID: 11.4 months; p=.93). The median overall survival in the BID arm was 6.3 
months longer (OD: 18.8 months, BID: 25.1 months; p=.61). There were no differences 
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in grade 3-4 esophagitis (OD: 31%, BID: 33%, p=.80) or pneumonitis (OD: 2%, BID: 




There was no difference in severe toxicity between the two TRT-schedules. The twice-
daily schedule resulted in significantly more complete responses and a numerically 
longer median overall survival, but no firm conclusions about efficacy could be drawn 
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Introduction 
Small-cell lung cancer (SCLC) accounts for up to 16% of lung cancer cases [1]. The 
main treatment is chemotherapy, and cisplatin plus etoposide is the standard regimen [2, 
3]. Concurrent thoracic radiotherapy (TRT) improves overall survival (OS) if all lesions 
can be included in one radiotherapy field ("limited disease" - LD SCLC) [4]. 
Prophylactic cranial irradiation (PCI) reduces the risk of brain metastases and prolongs 
survival in those who respond to chemo-radiotherapy [5]. Up to 90% of patients 
respond to the treatment, but most relapse and die from this disease [2, 6]. 
 Several schedules of TRT are being used in LD SCLC, but few comparative 
trials have been conducted. The most known study, by Turrisi et al., compared twice-
daily TRT (45 Gy/30 fractions, 3 weeks) with once-daily TRT (45 Gy/25 fractions, 5 
weeks). Response rates were equal (87%), but twice-daily TRT significantly prolonged 
median OS (23.0 months vs. 19.0 months; p=0.04) [6]. Thus, twice-daily TRT is the 
most recommended schedule, but not universally adopted [7-11]. Inconvenience of this 
schedule and concerns about esophagitis are probably the main explanations [10]. 
Furthermore, the different duration of the schedules (3 vs. 5 weeks) and dissimilar 
biologically effective doses might have contributed to the OS-difference [6]; a 
systematic overview concluded that shortening the treatment time from start of 
chemotherapy until completion of TRT was associated with a prolonged OS [12]. 
A three-week schedule of once-daily hypofractionated TRT (40 Gy in 15 
fractions) was one of the schedules included in the meta-analysis establishing TRT in 
LD SCLC [4]. Similar schedules have been used in Norway and other countries [2, 9, 
11, 13], but have never been compared with twice-daily TRT in a randomized trial. The 
aims of this study were to compare 45 Gy/30 fractions (twice daily - BID) with 42 
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Gy/15 fractions (once daily – OD) TRT in LD SCLC with respect to progression free 
survival (PFS), overall survival (OS), toxicity and health related quality of life 
(HRQoL). The hypothesis was that BID-regimen would be feasible and improve 
efficacy without severely increase toxicity. 
 
Material and Methods 
Design and approvals 
This randomized phase II trial was approved by the Regional Committee for Medical 
Research Ethics, Central Norway; the Norwegian Social Science Data Services; and the 
Norwegian Directorate for Health and Social Affairs. 
 
Eligibility criteria and random assignment 
A CT of the chest/upper abdomen, brain MRI and bone scan were conducted within 
three weeks prior to inclusion. Eligible patients gave written informed consent; were ≥ 
18 years old (no upper limit); had SCLC ineligible for surgery and confined to one 
hemithorax and the mediastinum, contralateral hilus and supraclavicular regions; 
measurable disease according to RECIST v1.0 [14]; no other active cancer; no prior 
chest-radiotherapy; WHO performance status (PS) 0-2; leukocytes ≥3.0 x 109/l, platelets 
≥100 x109/l, bilirubin <1.5 x ULN and creatinine <125 mol/l. One negative cytology 
was required if pleural effusion was present. 
Patients were randomized to receive TRT of 42 Gy/15 fractions (OD) or 45 





Phase II trial comparing once and twice daily TRT in LD SCLC 6 
  
Chemotherapy 
Patients were to receive four courses of cisplatin 75 mg/m2 IV day 1 and etoposide 100 
mg/m2 IV days 1-3 every 3 weeks (PE). A full dose was administered if leukocytes 
were ≥3.0 x 109/l and platelets ≥100 x 109/l on day 22. Doses were reduced by 25% if 
leukocytes were 2.5-2.99 x 109/l or platelets 75-99 x 109/l on day 22. At lower 
leukocyte- or platelet counts, courses were postponed. Dose-reductions were maintained 
for subsequent cycles. Use of G-CSF was not recommended. Chemotherapy was 
discontinued if a course was delayed more than three weeks or a third dose-reduction 
was warranted. Carboplatin was allowed if cisplatin was not tolerated. The use of other 
agents was not addressed in the protocol. 
 
Radiotherapy 
All patients received 3D conformal TRT five days a week starting between three and 
four weeks after day 1 of the first PE-course. The targets of the TRT were all known 
pathological lesions plus elective nodal irradiation of lymph node stations 4-7 
(bilateral). A planning CT scan was performed within one week prior to TRT. The gross 
tumor volume (GTV) included all pathological lesions on the baseline scan delineated 
according to the size on the planning CT scan. The clinical target volume (CTV) 
included GTV with a 1 cm margin in all directions (CTVtumor) plus the central part of 
the mediastinum comprising lymph node stations 4-7 (CTVmediastinum). An internal 
margin (IM) of 1.0 cm was added to the CTVtumor in the transverse plane and 1.0-1.5 cm 
in the cranio-caudal direction. An IM of 0.5 cm was added to the CTVmediastinum in all 
directions. Finally, a setup margin was added according to each hospitals routine. Less 
than 50% of the normal lung tissue should receive more than 20 Gy (V20lung <50%).  
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Other normal tissue constraints were defined and treatment verification was done 
according to local routines. 
A CT response evaluation was conducted three weeks after the last PE-course.  
Patients with a complete or near complete response were offered prophylactic cranial 




Primary endpoint was 1-year PFS. Secondary endpoints were OS, toxicity and 
HRQoL (global quality of life, dysphagia and dyspnea).  
 
Evaluation and follow up 
All patients were clinically examined and assessed for toxicity before each PE-course 
and weekly during TRT. Response evaluation was performed three weeks after the last 
PE. Confirmation of response was not required. Post-therapy, patients were followed 
every eight weeks year 1, every four months year 2-3, and every six months year 4-5. A 
CT of the chest/upper abdomen was done at each evaluation year 1. Later, a chest x-ray 
or CT scan (optional) was performed. Progressive disease (PD) was to be confirmed 
with a CT scan. 
Stage of disease was assessed according to TNM v6, response according to 
RECIST v1.0, and toxicity according to CTCAE v3.0 . PFS was defined as time from 
randomization until PD or death; OS as time from randomization until death.  
Patients reported HRQoL using the European Organization for Research and 
Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ) C30 and the lung 
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cancer specific module LC13. Patients completed the questionnaires at inclusion and at 
weeks 3, 6, 12, 20, 28 and 52. 
 
Statistical considerations 
To detect a 30% improvement in 1 year PFS (from 70% to 91%) from BID TRT with a 
two-sided alpha of 0.05 and a beta of 0.20, 75 patients were required in each arm. We 
expected a loss to follow-up of <10% and aimed at enrolling 83 patients in each arm. 
Patients who received at least one PE-course and one fraction of TRT were included in 
the analyses. 
 HRQoL-scores were calculated according to the QLQ-C30 scoring-manual . The 
clinically relevant minimum difference in mean scores was defined as 10 (on a scale 
from 0 to 100) [15]. 
Survival was estimated using the Kaplan-Meier method and compared using the 
log-rank test. Pearson’s Chi-square and Fisher’s exact tests were used for group 
comparisons. The Cox proportional hazard method was used for multivariate analyses. 




171 patients were enrolled between May 2005 and January 2011 at 18 hospitals in 
Norway. Fourteen patients were excluded: extensive disease (n=9), withdrawn consent 
(n=2), carcinoid tumour (n= 2), and prior chest radiotherapy (n=1). Thus, 157 were 
analysed (OD: 84 patients, BID: 73) (Figure 1). The imbalance in number of patients in 
each arm was partly due to the block randomization. 
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Median age was 63 years, 26% were ≥70 years, 52% were men, 84% had PS 0-
1, 72% had stage III disease and 11% had cytologically negative pleural fluid. Baseline 
characteristics were balanced between the arms (Table 1). 
Median follow-up for PFS was 59 months (range: 29-97); 34 patients were 
progression free when the analyses were performed (July, 2013). Median follow-up for 




More OD-patients completed chemotherapy without delays (OD: 42%, BID: 26%; 
p=.04). There were no other differences in chemotherapy. Fourteen patients received 
other chemotherapy due to cisplatin toxicity (OD: n=10, BID: n=4) (Table 2). 
The completion rate of TRT was similar (OD: 96%, BID: 97%). Mean doses 
were OD: 41.8 Gy (range: 34-45) and BID: 44.7 Gy (range: 30-46). 82% of OD patients 
and 84% of BID patients received PCI. PCI was omitted in 27 patients due to poor 
response (n=21), poor PS (n=3), patients’ decision (n=3) and death (n=1) (Table 2). 
 
Response to therapy, PFS and OS 
There was no difference in response rates (OD: 92% [95% CI: 86-98], BID: 88% [95% 
CI: 80-95]; p=.41), but more patients on the BID arm achieved a complete response 
(OD: 13% [95% CI: 6-20], BID: 33% [95% CI: 22-44]; p=.003) (Table 3). 
There were no differences in 1-year PFS (OD: 45% [95% CI: 34-56], BID: 49% 
[95% CI: 38-61]; p=.61) or median PFS (OD: 10.2 months [95% CI: 7.4-13.0], BID: 
11.4 months [95% CI: 8.2-14.7]; p=.93) (Figure 2). There were no significant 
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differences in location of first relapse: distant failures (OD: 47%, BID: 38%; p=.33), 
local failures (OD: 34%, BID: 50%; p=.10) or synchronous distant and local failures 
(OD: 19%, BID: 13%; p=.38). 
There were no statistically significant differences in 1-year OS (OD: 76% [95% 
CI: 67-85], BID: 77% [95% CI: 67-87]; p=.94), 2-year OS (OD: 42% [95% CI: 31-52], 
BID: 53% [95% CI: 42-65]; p=.14), 4-year OS (OD: 25% [95% CI: 16-34], BID: 25% 
[95% CI: 15-35]; p=.96) or median OS (OD: 18.8 months [95% CI: 13.6-23.9], BID: 
25.1 months [95% CI: 16.9-33.3]; p=.61) (Figure 2). The difference in median disease-




There were no differences in grade 3-4 neutropenic infections (OD: 44%, BID: 37%; 
p=.37), grade 3-4 esophagitis (OD: 31%, BID: 33%; p=.80) or grade 3-4 pneumonitis 
(OD: 2%, BID: 3%; p=1.0) (Table 3). There was no difference in treatment-related 
deaths (OD: n=4, BID: n=3; p=1.0). Four patients died from radiation pneumonitis (OD: 
n=3, BID: n=1). Three patients died within 30 days of chemoradiotherapy: hemoptysis 
(n=1), coronary disease (n=1) and respiratory failure (n=1). 
 
HRQoL 
The completion rate of the questionnaires was 85-97% of patients alive at each time 
point and similar in both arms. Patients in the BID-arm experienced more dysphagia at 
the end of TRT (mean score OD: 61, BID: 72) (Figure 3). There were no other 
differences in global QoL, dysphagia, dyspnea or in any other HRQoL-domain. 
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 Post-study treatment 
Seventy-five patients received second line chemotherapy (OD: 51%, BID: 44%; p=.36) 
(Table 2). Re-induction with etoposide plus cisplatin or carboplatin was the most 
common regimen (37/75 patients; 49%). 
 
PS and stage of disease 
All patients were analyzed as one cohort in these explorative analyses. There was no 
PS-related influence on response rates (PS 0-1: 89%, PS 2: 92%; p=1.0) or median OS 
(PS 0-1: 23.0 months, PS 2: 18.8 months; p=.32). Patients with stage I-II disease had 
similar response rates as stage III patients (stage I-II: 86%, stage III: 90%; p=.51), but 
longer median OS (stage I-II: 33.3 months, stage III: 20.4 months; p=.024). Elderly 
patients had similar response rates (< 70 years: 91%, ≥ 70 years: 88%; p=.76) and there 
were no significant differences in median OS (< 70 years: 24.6 months, ≥ 70 years: 14.6 
months; p=.28). Across genders, there were no differences in response rates (men: 89%, 
women: 91%; p=.69) or median OS (men: 21.7 months, women: 24.7 months; p=.53). 
There were no differences in grade 3-5 esophagitis or pneumonitis across PS, disease 
stage, age or gender. 
The multivariate analysis revealed that stage I-II patients had significantly 
longer survival than those with stage III (p=.026). No other characteristics were 
significantly associated with PFS or OS. 
 
Discussion 
In this RCT comparing two 3-week schedules, the twice-daily TRT-schedule provided 
significantly more complete responses, but not higher response-rates. There were no 
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statistically significant differences in PFS or OS, though the median OS (25.1 vs. 18.8 
months) and disease-specific survival (29.5 vs. 20.9 months) were more than 6 months 
longer on the BID-arm. The BID-patients reported slightly more dysphagia 
immediately after radiotherapy, but a difference in mean score of 10 to 20 is 
considered a "moderate change" [15]; they had slightly more dysphagia also before 
radiotherapy; and patients on both arms regained similar, pre-treatment levels of 
dysphagia soon after therapy. Thus, there were no differences in severe toxicity or 
treatment related deaths. We used a wide definition of limited disease, had no 
restrictions regarding comorbidity or age and 16% of the patients had PS 2. 
Approximately 17% of all patients diagnosed with LD SCLC in Norway during the 
enrolment period participated in the trial. 
 We are aware of two other prospective RCTs comparing one and two daily 
fractions of TRT in LD-SCLC. The split course used by Schild et al. [16] causes 
longer treatment duration and might enhance repopulation of cancer cells [12]. Thus, it 
is most relevant to compare our results with the study by Turrisi et al. In this study, 
TRT of 45 Gy in 30 fractions (BID) was compared with 45 Gy in 25 fractions (OD). 
All patients received cisplatin plus etoposide. Patients on the BID arm had 
significantly longer median OS (23.0 vs. 19.0 months; p=.04) [6]. The survival 
difference is of similar magnitude in our smaller study, though not statistically 
significant. Furthermore, the difference in median OS in our study did not result in a 
higher proportion of long-term survivors. 
Results from other studies might indicate that twice-daily regimens are superior 
to hypo-fractionated 3-week schedules. In two studies, patients on the control arms 
receiving four courses of cisplatin plus etoposide and TRT of 45 Gy/30 fractions 
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achieved response rates of 95-97%, median PFS of approximately 13 months, and 
median OS of 25-38 months [17, 18]. In studies administering TRT with 40-42 Gy/15 
fractions, response rates were 81-85%, median PFS 10.6 months and median OS 13.7-
21.2 months [2, 11, 13]. However, these studies are not necessarily comparable due to 
differences in patient selection, staging procedures, chemotherapy, timing and 
schedules of TRT, response-evaluation and follow-up. 
Turrisi et al. reported more esophagitis grade 3 (27% vs. 11%) but not more 
grade 4 (5% both arms) in the BID group. We found a similar proportion of grade 3-4 
esophagitis in the BID arm (33%), but a higher proportion in our OD arm (31%) – 
probably due to the higher daily dose. The percentage of deaths from radiation 
pneumonitis (4%) in the OD-arm is higher than in other reports [6, 13], but the number 
was low (n=3). 
 PFS was chosen as the primary endpoint since it correlates well with OS in 
several studies of SCLC and is less influenced by relapse treatment and death of other 
causes [6, 19]. However, using PFS as the primary endpoint can be debated. 
Distinguishing between relapse and radiation fibrosis in lung tissue is challenging, there 
was a large number of radiologists involved in this study, and no central review of CT 
images. On the other hand, assessment of progression was done equally in both arms. 
The assumptions for our sample size calculation were incorrect. The delta value in the 
calculation was rather large, but we considered the sample size adequate to guide 
directions for future research. Other reasons for limiting the sample size were concerns 
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 A limitation of the study is the lack of PET/CT for staging of disease. PET/CT 
identifies pathological lesions better than CT- and bone-scans [20], allowing for more 
accurate staging and definition of radiotherapy fields for TRT [21]. However, PET/CT 
was not generally available in Norway at the time when this study was conducted.  The 
use of elective nodal irradiation could have been avoided if PET/CT was used for 
staging.  
Further, there may have been some technical development in radiotherapy 
during the six year inclusion period. The annual number of patients per hospital was 
low, and we had no central quality assurance of radiotherapy. We have no information 
on patients not included into the trial. It is difficult to draw any firm conclusions about 
efficacy from this phase II trial. The higher rate of complete responses and the longer 
median overall survival may indicate superiority of the BID-schedule. But no 
corresponding difference in PFS was observed, and there was a trend towards more 
local relapses at first recurrence in the BID-arm. Besides, the difference in median 
overall survival was not statistically significant, and there were no differences in 4-
year survival rates. Thus, a phase III study is needed before one can conclude whether 
the BID-schedule is more effective than the OD-schedule. Considering the results of 
the present study, the hypothesis of such a trial should be that BID is superior to OD. 
A large number of patients would be required, and by conducting such a study, many 
patients might receive an inferior treatment - which would probably be equally toxic as 
the BID-schedule. Thus, we assume that the relevance of such a trial is limited. 
By using PET/CT for target volume definition and advanced radiotherapy 
techniques, higher TRT doses can be delivered and there are indications that 60-70 Gy 
in 6-7 weeks may be superior to 45 Gy/30 fractions [22-24]. In line with this, we have 
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initiated a Nordic, randomized phase II trial comparing 45 Gy/30 fractions with 60 
Gy/40 fractions. All patients receive two fractions per day. The primary endpoint is 2-
year survival. 
Despite improvements in radiotherapy-techniques it may not be possible to 
deliver 60-70 Gy to all patients with disseminated intra-thoracic disease, severe 
comorbidity or poor PS. Thus, some patients might receive TRT doses of 40-45 Gy 
also in the future. Our study indicates that concerns about toxicity should not be a 
reason for choosing hypo-fractionated instead of twice-daily TRT. 
 In conclusion, there was no difference in toxicity between the two TRT-
schedules. The twice-daily schedule was feasible and resulted in more complete 
responses and a numerically longer median overall survival. There was no difference in 
progression free survival, and the survival-difference was not statistically significant. 
Thus, no firm conclusions about efficacy could be drawn from this phase II trial. 
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Figure 1 Patient selection
Analyzed  (n=84)
Allocated to once daily thoracic radiotherapy (OD) (n=89)
Ineligible (n=5)
▪ Extensive disease (n=5)





▪Prior radiotherapy to the chest (n=1)
Analyzed  (n=73)
Randomized (n=171)
Median (95% CI) PFS 1 year (95% CI) PFS 2 year (95% CI) PFS
 Twice daily 11.4 (8.2-14.7) months 49 (38-61)% 29 (18-39)%
 Once daily 10.2 (7.4-13.0) months 45 (34-56)% 26 (17-36)%
Median (95% CI) OS 1 year (95% CI) OS 2 year (95% CI) OS
 Twice daily 25.1 (16.9-33.3) months 77 (67-87)% 53 (42-65)%
 Once daily 18.8 (13.6-23.9) months 76 (67-85)% 42 (31-52)%
Figure 2 Progression free survival and overall survival
p =.93 (log rank) p =.61 (log rank)
Number at risk
0 10 20 30 40 50 60
 73 58 47 34 24 17 17
 84 68 41 33 24 21 17
Number at risk
0 10 20 30 40 50 60
 73 40 26 20 13 8 6
 84 44 28 18 15 8 5
 Twice daily (BID)
 Once daily (OD)
Figure 3 Mean HRQoL-scores. A higher score on the global QoL-scale represents a better
HRQOL, a higher score on the symptom-scales is associated with a worse HRQoL. A 
difference in mean scores of 10 points was considered clinically relevant.
 Twice daily (BID)
 Once daily (OD)
 Twice daily (BID)
 Once daily (OD)





Age Median (range) 63 (40-85) 63 (44-79)
≥ 70 years 26 31 % 15 21 %
Sex Women 39 46 % 37 51 %
Men 45 54 % 36 49 %
PS 0 31 37 % 20 27 %
1 42 50 % 39 53 %
2 11 13 % 14 19 %
Pleural fluid Present 11 13 % 7 10 %
Stage I 7 8 % 6 8 %
II 7 8 % 9 12 %
IIIA 34 40 % 21 29 %
IIIB 30 36 % 28 38 %
Unknown 6 7 % 9 12 %







Chemotherapy 1 course - - 1 1 % -
2 courses 3 4 % 1 1 % -
3 courses 6 7 % 11 15 % -
4 courses 75 89 % 60 82 % .20
Mean no. of course 3.86 3.78 .33
4 courses without delay 35 42 % 19 26 % 0.04
4 courses without dose reduction 33 39 % 24 33 % 0.41
Carboplatin instead of cisplatin in ≥ 1 course 9 11 % 3 4 % -
Adriamysin (or epirubicin) 
/cyclophosphamid/vincristine
instead of cisplatin/etoposide in ≥ 1 course
1 1% 1 1 % -
Radiotherapy Thoracic radiotherapy completed as planned 81 96 % 71 97 % 1.0
Prophylactic cranial irradiation received 69 82 % 61 84 % .81
Second line 
chemotherapy
Received 43 51% 32 44% .36
cis or carboplatin/etoposide 18 42% 19 59% .13
adriamysin/cyclophosphamid/vincristine 18 42% 8 25% .13







Response Complete response - 11 13% 24 33% .003
Partial response - 66 79% 40 55% .002
Stable disease - 1 1% 1 1% 1.0
Progressive disease - 5 6% 3 4% .73
Not evaluable - 1 1% 5 7% .10
Toxicity Esophagitis 0-2 58 69 % 49 67 % 0.80
3-4 26 31 % 24 33 % 0.80
5 - - - - -
Pneumonitis
0-2 79 94 % 70 96 % 0.73
3-4 2 2 % 2 3 % 1.0
5 3 4 % 1 1 % 0.62
Anemia 3-4 9 11 % 16 22 % 0.06
Leukopenia 3-4 58 69 % 57 68 % 0.20
Thrombocytopenia 3-4 29 35 % 28 38 % 0.62
Neturopenia 3-4 72 86 % 59 81 % 0.41
Neutropenic infections 3-4 37 44 % 27 37 % 0.37
Infection without neutropenia 3-4 8 10 % 7 10 % .99
Table 3 Response evaluation three weeks after the last chemotherapy-course
according to the RECIST-criteria (v 1.0) and toxicity
